FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

Follow FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)
Share on
Copy link to clipboard

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

U.S. Food and Drug Administration, Center for Drug Evaluation and Research


    • Jan 17, 2025 LATEST EPISODE
    • monthly NEW EPISODES
    • 4m AVG DURATION
    • 119 EPISODES


    Search for episodes from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) with a specific topic:

    Latest episodes from FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

    FDA D.I.S.C.O. Burst Edition: FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients

    Play Episode Listen Later Jan 17, 2025 3:00


    Listen to a soundcast of the 12.18.2024 FDA approval of Ryoncil (remestemcel-L-rknd) for steroid-refractory acute graft versus host disease in pediatric patients.

    fda disc steroids acute burst graft fda approval refractory pediatric patients host disease
    FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior s

    Play Episode Listen Later Dec 30, 2024 3:00


    FDA D.I.S.C.O. Burst Edition: FDA approval of Bizengri (zenocutuzumab-zbco) for Treatment of adults with advanced unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy

    treatments adults disc fusion burst fda approval pancreatic metastatic harboring disease progression adenocarcinoma unresectable
    FDA D.I.S.C.O. Burst Edition: FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma

    Play Episode Listen Later Nov 18, 2024 3:00


    Listen to a soundcast of the 8.2.2024 FDA approval of Tecelra (afamitresgene autoleucel) for unresectable or metastatic synovial sarcoma.

    fda disc burst fda approval metastatic sarcoma unresectable synovial
    FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma

    Play Episode Listen Later Nov 14, 2024 3:30


    Listen to a soundcast of the 9.17.2024 FDA approval of Keytruda (pembrolizumab) for unresectable advanced or metastatic malignant pleural mesothelioma.

    fda disc burst malignant fda approval metastatic mesothelioma pleural keytruda pembrolizumab unresectable
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer

    Play Episode Listen Later Aug 16, 2024 4:59


    Listen to a soundcast of the June 13, 2024, and June 21, 2024, Augtyro (repotrectinib) for NTRK gene fusion-positive solid tumors and Krazati (adagrasib) for KRAS G12C-mutated colorectal cancer.

    positive disc fusion burst colorectal cancer approvals kras mutated solid tumors
    FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic RET fusion-positive thyroid cancer

    Play Episode Listen Later Jul 2, 2024 4:00


    Listen to a soundcast of the May 29, 2024, FDA approval of Retevmo (selpercatinib) for patients with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory.

    positive fda disc fusion burst ret fda approval metastatic thyroid cancer
    FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation

    Play Episode Listen Later Jun 17, 2024 4:00


    Listen to a soundcast of the April 23, 2024, FDA approval of Ojemda (tovorafenib) for relapsed or refractory pediatric low-grade glioma harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

    fda grade disc fusion pediatric burst mutation fda approval refractory harboring relapsed braf glioma rearrangement
    FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors

    Play Episode Listen Later Apr 26, 2024 3:30


    Listen to a soundcast of the April 5, 2024, FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-positive solid tumors.

    positive fda disc burst fda approval metastatic her2 solid tumors trastuzumab unresectable enhertu
    FDA D.I.S.C.O. Burst Edition: FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment

    Play Episode Listen Later Jan 8, 2024 3:30


    Listen to a soundcast of the November 27, 2023 FDA approval of OGSIVEO (nirogacestat) for adult patients with progressing desmoid tumors who require systemic treatment.

    treatments fda disc require systemic tumors burst progressing fda approval adult patients
    FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer

    Play Episode Listen Later Jan 5, 2024 2:59


    FDA D.I.S.C.O. Burst Edition: FDA approval of Augtyro (repotrectinib) for locally advanced or metastatic ROS1-positive non-small cell lung cancer

    positive disc locally burst fda approval metastatic small cell lung cancer ros1
    FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer

    Play Episode Listen Later Jan 5, 2024 3:30


    FDA D.I.S.C.O. Burst Edition: FDA approval of Fruzaqla (fruquintinib) for adult patients with metastatic colorectal cancer

    disc burst colorectal cancer fda approval metastatic adult patients
    FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation

    Play Episode Listen Later Nov 20, 2023 3:30


    FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) for patients with relapsed or refractory myelodysplastic syndromes with a susceptible isocitrate dehydrogenase-1 mutation

    patients disc burst mutation fda approval susceptible refractory relapsed myelodysplastic syndromes
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma

    Play Episode Listen Later Sep 26, 2023 6:59


    FDA D.I.S.C.O. Burst Edition: FDA approvals of Talvey (talquetamab-tgvs) for relapsed or refractory multiple myeloma, and Elrexfio (elranatamab-bcmm) for relapsed or refractory multiple myeloma

    disc burst approvals multiple myeloma refractory relapsed
    FDA D.I.S.C.O. Burst Edition: FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer

    Play Episode Listen Later Jul 13, 2023 3:30


    Listen to a soundcast of the May 31, 2023, FDA approval of Lynparza (olaparib), with abiraterone and prednisone, for BRCA-mutated metastatic castration-resistant prostate cancer.”

    fda disc burst prostate cancer resistant brca fda approval castration metastatic mutated prednisone olaparib abiraterone
    FDA D.I.S.C.O. Burst Edition: FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma

    Play Episode Listen Later Jun 21, 2023 3:30


    Listen to a soundcast of the May 19, 2023, FDA approval of Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma.

    large fda disc burst lymphoma diffuse fda approval refractory relapsed highgrade grade b
    FDA D.I.S.C.O. Burst Edition: FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

    Play Episode Listen Later Jun 7, 2023 3:30


    Listen to a soundcast of the April 19, 2023, FDA approval of Polivy (polatuzumab vedotin-piiq) for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma.

    large fda disc burst lymphoma diffuse fda approval untreated highgrade grade b
    FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies

    Play Episode Listen Later May 25, 2023 3:30


    Listen to a soundcast of the April 17, 2023, FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies.

    recovery patients fda reduce disc infection burst fda approval hematologic malignancies neutrophil
    FDA D.I.S.C.O. Burst Edition: FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial carcinoma

    Play Episode Listen Later May 3, 2023 4:00


    Listen to a soundcast of the April 19, 2023, FDA approval of Padcev (enfortumab vedotin-ejfv) with Keytruda (pembrolizumab) for locally advanced or metastatic urothelial carcinoma.”

    fda disc locally burst fda approval metastatic carcinoma keytruda pembrolizumab
    FDA D.I.S.C.O. Burst Edition: FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma

    Play Episode Listen Later Apr 20, 2023 2:30


    Lsten to a soundcast of the March 22, 2023 FDA approval of Zynyz (retifanlimab-dlwr) for metastatic or recurrent locally advanced Merkel cell carcinoma.

    fda disc angela merkel locally burst recurrent fda approval metastatic merkel cell carcinoma
    FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) with Mekinist (trametinib) for pediatric patients with low-grade glioma with a BRAF V600E mutation

    Play Episode Listen Later Apr 6, 2023 4:00


    Listen to a soundcast of the March 16, 2023, FDA approval of Tafinlar (dabrafenib) for pediatric patients with low-grade glioma with a BRAF V600E mutation

    fda grade disc burst mutation fda approval pediatric patients glioma braf v600e trametinib dabrafenib mekinist tafinlar
    FDA D.I.S.C.O. Burst Edition: FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer

    Play Episode Listen Later Mar 24, 2023 4:30


    Listen to a soundcast of the March 3, 2023, FDA approval of Verzenio (abemaciclib) with endocrine therapy for patients with HR-positive, HER2-negative, node-positive, early breast cancer.

    positive therapy patients negative fda disc breast cancer burst node endocrine fda approval her2
    FDA D.I.S.C.O. Burst Edition: FDA approval of Jemperli (dostarlimab-gxly) for dMMR endometrial cancer

    Play Episode Listen Later Mar 7, 2023 3:30


    Listen to a soundcast of the February 9, 2023, FDA approval of Jemperli (dostarlimab-gxly) for mismatch repair deficient (dMMR) recurrent or advanced endometrial cancer that has progressed on or following a prior platinum-containing regimen.

    fda disc burst fda approval endometrial cancer dmmr dostarlimab
    FDA D.I.S.C.O. Burst Edition: FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer

    Play Episode Listen Later Mar 1, 2023 4:00


    Listen to a soundcast of the February 3, 2023, FDA approval of Trodelvy (sacituzumab govitecan-hziy) for HR-positive breast cancer.

    positive fda disc breast cancer burst fda approval
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma, and Orserdu (elacestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer

    Play Episode Listen Later Mar 1, 2023 6:59


    Listen to a soundcast of the January 27, 2023, FDA approvals of Jaypirca (pirtobrutinib) for relapsed or refractory mantle cell lymphoma, and Orserdu (elacestrant) for ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

    er positive negative fda disc burst approvals her2 refractory metastatic breast cancer mutated relapsed mantle cell lymphoma esr1
    FDA D.I.S.C.O. Burst Edition: FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

    Play Episode Listen Later Mar 1, 2023 3:30


    Listen to a soundcast of the January 26, 2023, FDA approval of Keytruda (pembrolizumab) as adjuvant treatment for non-small cell lung cancer

    treatments fda disc burst fda approval adjuvant small cell lung cancer keytruda pembrolizumab
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma

    Play Episode Listen Later Feb 16, 2023 6:29


    Listen to a soundcast of the January 19, 2023, FDA approvals of Tukysa (tucatinib) with trastuzumab for colorectal cancer and Brukinsa (zanubrutinib) for chronic lymphocytic leukemia or small lymphocytic lymphoma.

    fda disc burst colorectal cancer approvals chronic lymphocytic leukemia trastuzumab small lymphocytic lymphoma
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer

    Play Episode Listen Later Jan 23, 2023 6:59


    Listen to a soundcast of the December 9 and 12, 2022, FDA approvals of Tecentriq (atezolizumab) for unresectable or metastatic alveolar soft part sarcoma, and Krazati (adagrasib) for KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer”

    soft fda disc locally burst approvals metastatic sarcoma kras mutated small cell lung cancer alveolar unresectable atezolizumab
    FDA D.I.S.C.O. Burst Edition: FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors

    Play Episode Listen Later Jan 20, 2023 3:30


    Listen to a soundcast of the December 16, 2022, FDA approval of Adstiladrin (nadofaragene firadenovec-vncg) for patients with high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without papillary tumors.

    patients fda muscle disc tumors burst situ high risk invasive fda approval carcinoma bladder cancer bacillus unresponsive papillary
    FDA D.I.S.C.O. Burst Edition: FDA approval of Lunsumio (mosunetuzumab-axgb) for adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy

    Play Episode Listen Later Jan 19, 2023 3:30


    Listen to a soundcast of the December 22, 2022, FDA approval of Lunsumio (mosunetuzumab-axgb) for ipatients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.”

    lines fda disc burst fda approval refractory relapsed follicular lymphoma adult patients systemic therapy
    FDA D.I.S.C.O. Burst Edition: FDA approves updated drug labeling including new indications and dosing regimens for Xeloda (capecitabine) tablets under Project Renewal

    Play Episode Listen Later Jan 17, 2023 4:00


    Listen to a soundcast of the December 14, 2022, FDA approval of Xeloda (capecitabine) under Project Renewal, an initiative aimed at updating labeling information for certain older oncology drugs to ensure information is clinically meaningful and scientifically up to date.

    drug fda disc burst tablets approves labeling indications dosing project renewal
    FDA D.I.S.C.O. Burst Edition: FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation

    Play Episode Listen Later Jan 10, 2023 3:30


    Listen to a soundcast of the December 1, 2022, FDA approval of Rezlidhia (olutasidenib) for relapsed or refractory acute myeloid leukemia with a susceptible IDH1 mutation.

    fda disc burst mutation fda approval susceptible refractory acute myeloid leukemia relapsed idh1
    FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

    Play Episode Listen Later Jan 6, 2023 4:00


    FDA D.I.S.C.O. Burst Edition: FDA approval of Elahere (mirvetuximab soravtansine-gynx) for FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or peritoneal cancer

    positive cancer disc platinum tube burst resistant ovarian fda approval fallopian epithelial peritoneal
    FDA D.I.S.C.O. Burst Edition: FDA approves a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant)

    Play Episode Listen Later Dec 28, 2022 4:00


    Listen to a soundcast of the November 18, 2022 FDA approval of a new dosing regimen for asparaginase erwinia chrysanthemi (recombinant).

    fda disc burst approves regimen dosing recombinant erwinia
    FDA D.I.S.C.O. Burst Edition: FDA approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

    Play Episode Listen Later Dec 15, 2022 3:00


    FDA D.I.S.C.O. Burst Edition: FDA approval of Adcetris (brentuximab vedotin) in combination with chemotherapy for pediatric patients with classical Hodgkin lymphoma

    disc classical burst combination chemotherapy hodgkin fda approval pediatric patients hodgkin lymphoma
    FDA D.I.S.C.O. Burst Edition: FDA approval of Libtayo (cemiplimab-rwlc) in combination with platinum-based chemotherapy for non-small cell lung cancer

    Play Episode Listen Later Dec 5, 2022 3:30


    Listen to a soundcast of the November 8th 2022 FDA approval of Libtayo (cemiplimab-rwlc)  in combination with platinum-based chemotherapy for non-small cell lung cancer

    fda disc platinum burst combination chemotherapy fda approval small cell lung cancer
    FDA D.I.S.C.O. Burst Edition: FDA approval of Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for metastatic non-small cell lung cancer

    Play Episode Listen Later Dec 5, 2022 3:00


    Listen to a soundcast of the November 10th 2022 FDA approval of Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) and platinum-based chemotherapy for metastatic non-small cell lung cancer

    fda disc platinum burst combination chemotherapy fda approval metastatic small cell lung cancer
    FDA D.I.S.C.O. Burst Edition: FDA approval of Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or othe

    Play Episode Listen Later Nov 23, 2022 3:00


    Listen to a soundcast of the 9/30/22 FDA approval of Lytgobi (futibatinib) for adult patients with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 gene fusions or other rearrangements.

    fda disc locally treated burst receptor fda approval metastatic harboring fusions growth factor adult patients cholangiocarcinoma unresectable fibroblast
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and Tecvayli (teclistamab-cqyv) for relapsed or refractory multiple myeloma

    Play Episode Listen Later Nov 23, 2022 5:29


    Listen to a soundcast of the October 21st and 25th 2022, FDA approvals of Imjudo (tremelimumab) in combination with durvalumab for unresectable hepatocellular carcinoma, and Tecvayli (teclistamab-cqyv) for relapsed or refractory multiple myeloma.

    fda disc burst combination approvals multiple myeloma refractory relapsed hepatocellular carcinoma unresectable
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-positive solid tumors, and Retevmo (selpercatinib) for adult patients with locally advanced or metastatic RET fusion-p

    Play Episode Listen Later Nov 3, 2022 6:30


    Listen to a soundcast of the 9/21/22 FDA approval of Retevmo (selpercatinib) for adult patients with locally advanced or metastatic solid tumors with a rearranged during transfection gene fusion that have progressed on or following prior systemic treatment.

    positive fda disc fusion locally burst approvals metastatic adult patients solid tumors
    FDA D.I.S.C.O. Burst Edition: FDA approval of Pedmark (sodium thiosulfate) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors

    Play Episode Listen Later Oct 19, 2022 3:30


    Listen to a soundcast of the September 20, 2022, the FDA approved sodium thiosulfate (brand name Pedmark) to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month and older with localized, non-metastatic solid tumors.

    risk fda reduce older disc burst sodium fda approval metastatic localized pediatric patients solid tumors cisplatin
    FDA D.I.S.C.O. Burst Edition: FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer

    Play Episode Listen Later Oct 17, 2022 3:30


    Listen to a soundcast of the September 2nd, 2022 FDA approval of Imfinzi (durvalumab) for adult patients with locally advanced or metastatic biliary tract cancer.

    cancer fda disc locally burst tract fda approval metastatic biliary adult patients
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease, and Pemazyre (pemigatinib) for adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement

    Play Episode Listen Later Sep 28, 2022 5:59


    Listen to a soundcast of the 8/24/22 and 8/26/22 FDA approvals of Imbruvica (ibrutinib) for pediatric patients with chronic graft versus host disease, including a new oral suspension, and Pemazyre (pemigatinib) for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.”

    fda adults chronic disc burst graft approvals refractory relapsed pediatric patients host disease myeloid ibrutinib rearrangement lymphoid imbruvica fgfr1
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2-low breast cancer, and Nubeqa (darolutamide) in combination with docetaxel for metastatic hormone-sensitive prostate cancer

    Play Episode Listen Later Sep 7, 2022 6:59


    Listen to a soundcast of the 8/5/2022 FDA approvals of Enhertu (fam-trastuzumab deruxtecan-nxki) for patients unresectable or metastatic HER2-low breast cancer, and Nubeqa (darolutamide) for adult patients with metastatic hormone-sensitive prostate cancer.”

    fda hormones disc breast cancer sensitive burst combination prostate cancer approvals metastatic her2 trastuzumab unresectable docetaxel enhertu
    FDA D.I.S.C.O. Burst Edition: Tabrecta (capmatinib) for metastatic non-small cell lung cancer and Enhertu (fam-trastuzumab deruxtecan-nxki) for HER2-mutant non-small cell lung cancer

    Play Episode Listen Later Sep 7, 2022 6:59


    Listen to a soundcast of the 8/10/2022 and 8/11/2022 FDA approvals of Tabrecta (capmatinib) for metastatic non-small cell lung cancer, and Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic non-small cell lung cancer.

    fda disc mutant burst metastatic her2 small cell lung cancer trastuzumab enhertu
    FDA D.I.S.C.O. Burst Edition: FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor

    Play Episode Listen Later Aug 1, 2022 3:00


    Listen to a soundcast of the July 14, 2022 FDA approval of Xalkori (crizotinib) for ALK-positive inflammatory myofibroblastic tumor.

    positive fda disc tumors burst inflammatory fda approval alk crizotinib xalkori
    FDA D.I.S.C.O. Burst Edition: FDA approval of Tafinlar (dabrafenib) in combination with Mekinist (trametinib) for unresectable or metastatic solid tumors with BRAF V600E mutation

    Play Episode Listen Later Jul 25, 2022 4:59


    Listen to a soundcast of the June 22nd 2022 FDA approval of Tafinlar (dabrafenib) for in combination w/trametinib (brand name Mekinist) for unresectable or metastatic solid tumors with BRAF V600E mutation.

    fda disc burst mutation combination fda approval metastatic solid tumors unresectable braf v600e trametinib dabrafenib mekinist tafinlar
    FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma

    Play Episode Listen Later Jul 21, 2022 4:59


    FDA D.I.S.C.O. Burst Edition: FDA approval of Breyanzi (lisocabtagene maraleucel) for second-line treatment of large B-cell lymphoma

    treatments large disc burst lymphoma fda approval second line
    FDA D.I.S.C.O. Burst Edition: FDA approvals of Opdivo in combination with chemotherapy and Opdivo in combination with Yervoy for first-line advanced or metastatic esophageal squamous cell carcinoma, and Kymriah (tisagenlecleucel) for relapsed or refractor

    Play Episode Listen Later Jun 23, 2022 6:29


    Listen to a soundcast of the May 27, 2022 FDA approvals of Opdivo (nivolumab) and Yervoy (nivolumab and ipilimumab) for advanced or metastatic esophageal squamous cell carcinoma, and Kymriah (tisagenlecleucel) for relapsed or refractory follicular lymphoma."”

    fda disc burst combination chemotherapy approvals first line metastatic esophageal relapsed squamous cell carcinoma opdivo refractor yervoy kymriah
    FDA D.I.S.C.O. Burst Edition: FDA approval of Tibsovo (ivosidenib) in combination with azacitidine for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have co

    Play Episode Listen Later Jun 17, 2022 4:00


    Listen to a soundcast of the 05/25/022, FDA approval of Tibsovo (ivosidenib) for newly diagnosed acute myeloid leukemia with a susceptible IDH1 mutation, as detected by an FDA-approved test in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

    fda adults older disc burst mutation combination detected fda approval susceptible fda approved acute myeloid leukemia newly diagnosed idh1
    FDA D.I.S.C.O. Burst Edition: FDA approval of Vidaza (azacytidine) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia

    Play Episode Listen Later Jun 3, 2022 3:30


    Listen to a soundcast of the May 20, 2022, the FDA approved azacitidine (brand name Vidaza) for pediatric patients with newly diagnosed juvenile myelomonocytic leukemia.

    fda disc juveniles burst leukemia fda approval newly diagnosed pediatric patients azacytidine
    FDA D.I.S.C.O. Burst Edition: FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer

    Play Episode Listen Later May 24, 2022 4:29


    Listen to a soundcast of the 5/4/2022 FDA approval of Enhertu (fam-trastuzumab deruxtecan-nxki) for adult patients with unresectable or metastatic HER2-positive breast cancer.

    positive fda disc breast cancer burst fda approval metastatic her2 adult patients trastuzumab unresectable enhertu

    Claim FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)

    In order to claim this podcast we'll send an email to with a verification link. Simply click the link and you will be able to edit tags, request a refresh, and other features to take control of your podcast page!

    Claim Cancel